GLPwatch
Papers (10378)
Page 90 of 173, ranked by citation count.
- Liraglutide 3.0 mg (Saxenda©) for Weight Loss and Remission of Pre-Diabetes. Real-World Clinical Evaluation of Effectiveness among Patients Awaiting Bariatric Surgery.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- GLP-1 Receptor Agonist Treatment Improves Fasting and Postprandial Lipidomic Profiles Independently of Diabetes and Weight Loss.
- Evaluating the Cost of Bringing People with Type 2 Diabetes Mellitus to Multiple Targets of Treatment in Canada.
- Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study.
- Feasibility of a Scale-down Production of [<sup>68</sup>Ga]Ga-NODAGA-Exendin-4 in a Hospital Based Radiopharmacy.
- Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes.
- Diabetic Kidney Disease - Semaglutide Flows into the Mainstream.
- PET evaluation of light-induced modulation of microglial activation and GLP-1R expression in depressive rats.
- Signaling Mechanism for Modulation by GLP-1 and Exendin-4 of GABA Receptors on Rat Retinal Ganglion Cells.
- Effect of Glucagon-Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis.
- The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study.
- Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide.
- A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study.
- Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor.
- Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review.
- Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?
- Single-cell transcriptome reveals effects of semaglutide on non-cardiomyocytes of obese mice.
- Evaluating the safety profile of semaglutide: an updated meta-analysis.
- Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial.
- [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
- Glucagon-Like Peptide-1 Receptor Agonists and Age-Related Macular Degeneration.
- Exendin-4 decreases ghrelin levels through mTOR signaling.
- Late and severe acute necrotizing pancreatitis in a patient with liraglutide.
- Case report of the successful use of semaglutide to achieve target BMI prior to renal transplant in two patients with end-stage-kidney-disease.
- Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes.
- Pharmacological treatment of obesity in adults in Norway 2004-2022.
- Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients.
- The clinical burden of type 2 diabetes in patients with acute coronary syndromes: prognosis and implications for short- and long-term management.
- Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
- Triple Agonism Based Therapies for Obesity.
- Exenatide reduces cardiomyocyte apoptosis by stimulating adiponectin secretion and activating APPL1-AMPK-PPARα axis.
- Tirzepatide-Induced Rapid Weight Loss-Related Thyrotoxicosis.
- GLP-1RA in the Real World: 1-year Compliance and Outcomes of Semaglutide use in Patients With or Without Previous History of Bariatric Surgery.
- Mitigation of Hearing Damage After Repeated Blast Exposures in Animal Model of Chinchilla.
- Liraglutide effects on epicardial adipose tissue micro-RNAs and intra-operative glucose control.
- Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective.
- Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide to Characterize Its Antiobesity Effects in Diet-Induced Obese Mice.
- Glucagon-like peptide-1 regulation of carbohydrate intake is differentially affected by obesogenic diets.
- Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?
- Dulaglutide accelerates diabetic wound healing by suppressing Nrf2-dependent ferroptosis in diabetic mice.
- Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials.
- Fusion Outcomes of GLP-1 Agonist Therapy in Multilevel Cervical Spinal Fusion: A Propensity-Matched Analysis.
- Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial).
- Real-world observations of GLP-1 receptor agonists and SGLT-2 inhibitors as potential treatments for Alzheimer's disease.
- Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.
- Glucagon-Like Peptide-1 Receptor-Targeted PET/CT With 68 Ga-HBED-CC-Exendin-4 in Localizing Insulinoma : A Head-to-Head Comparison to 68 Ga-NOTA-Exendin-4.
- Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide.
- Antigen-specific immunotherapy combined with a regenerative drug in the treatment of experimental type 1 diabetes.
- Effectiveness and persistence of anti-obesity medications (liraglutide 3 mg, lorcaserin, and orlistat) in a real-world primary care setting.
- Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis.
- A site-specific PEGylated analog of exendin-4 with improved pharmacokinetics and pharmacodynamics in vivo.
- What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?
- Cardioprotective Actions of a Glucagon-like Peptide-1 Receptor Agonist on Hearts Donated After Circulatory Death.
- Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.
- Microglial activation and hypothalamic structural plasticity in HFD obesity: insights from semaglutide and minocycline.
- Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?
- Islet Autoimmunity in Adults With Impaired Glucose Tolerance and Recently Diagnosed, Treatment Naïve Type 2 Diabetes in the Restoring Insulin SEcretion (RISE) Study.
- Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups.
- Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies.